Chino S Aneke-Nash1, Christina M Parrinello2, Swapnil N Rajpathak3,4, Thomas E Rohan1, Elsa S Strotmeyer5, Stephen B Kritchevsky6, Bruce M Psaty7, Petra Bůžková7, Jorge R Kizer8, Anne B Newman5, Howard D Strickler1, Robert C Kaplan1. 1. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York. 2. Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland. 3. Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 4. Merck & Co., Inc., Whitehouse Station, New Jersey. 5. Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania. 6. Sticht Center on Aging, Section on Gerontology and Geriatric Medicine, School of Medicine, Wake Forest University, Winston-Salem, North Carolina. 7. Department of Biostatistics, University of Washington, Seattle, Washington. 8. Departments of Medicine and Public Health, Weill Medical College, Cornell University, New York, New York.
Abstract
OBJECTIVES: To determine whether changes in insulin-like growth factor (IGF) protein levels are greater in participants with type 2 diabetes mellitus or worsening glycemia than in normoglycemic individuals over a 9-year follow-up period. DESIGN: Retrospective analysis of a cohort study. SETTING: Participants were recruited from North Carolina, California, Maryland, and Pennsylvania. PARTICIPANTS: Cardiovascular Health Study All Stars participants, a cohort study of community-dwelling adults aged 65 and older (N=897). MEASUREMENTS: Plasma IGF-I, IGF binding protein (IGFBP)-1, and IGFBP-3 levels were assessed and American Diabetes Association cut-points for impaired glucose tolerance (IGT), impaired fasting glucose (IFG), and diabetes mellitus were used to classify participants at baseline (1996-97) and follow-up (2005-06). RESULTS: At baseline, mean age was 76.3±3.6, and 18.5% had diabetes mellitus. Participants with IFG alone and IGT plus IFG had higher IGF-I levels and lower IGFBP-1 levels than those with normoglycemia or diabetes mellitus. The greatest percentage change in IGF levels occurred in those who had diabetes mellitus at baseline (9-year changes: -9.3% for IGF-I, 59.7% for IGFBP-1, -13.4% for IGFBP-3), the smallest in individuals who remained normoglycemic at follow-up (9-year changes: -3.7% for IGF-I, 25.6% for IGFBP-1, -6.4% for IGFBP-3), and intermediate in those who were normoglycemic but developed IFG at follow-up. CONCLUSION: Degrees of glycemic impairment are associated with varying degrees of change in IGF protein levels. The changes observed in the diabetes mellitus group have been previously shown to be associated with heart failure, cancer, and noncancer mortality.
OBJECTIVES: To determine whether changes in insulin-like growth factor (IGF) protein levels are greater in participants with type 2 diabetes mellitus or worsening glycemia than in normoglycemic individuals over a 9-year follow-up period. DESIGN: Retrospective analysis of a cohort study. SETTING:Participants were recruited from North Carolina, California, Maryland, and Pennsylvania. PARTICIPANTS: Cardiovascular Health Study All Stars participants, a cohort study of community-dwelling adults aged 65 and older (N=897). MEASUREMENTS: Plasma IGF-I, IGF binding protein (IGFBP)-1, and IGFBP-3 levels were assessed and American Diabetes Association cut-points for impaired glucose tolerance (IGT), impaired fasting glucose (IFG), and diabetes mellitus were used to classify participants at baseline (1996-97) and follow-up (2005-06). RESULTS: At baseline, mean age was 76.3±3.6, and 18.5% had diabetes mellitus. Participants with IFG alone and IGT plus IFG had higher IGF-I levels and lower IGFBP-1 levels than those with normoglycemia or diabetes mellitus. The greatest percentage change in IGF levels occurred in those who had diabetes mellitus at baseline (9-year changes: -9.3% for IGF-I, 59.7% for IGFBP-1, -13.4% for IGFBP-3), the smallest in individuals who remained normoglycemic at follow-up (9-year changes: -3.7% for IGF-I, 25.6% for IGFBP-1, -6.4% for IGFBP-3), and intermediate in those who were normoglycemic but developed IFG at follow-up. CONCLUSION: Degrees of glycemic impairment are associated with varying degrees of change in IGF protein levels. The changes observed in the diabetes mellitus group have been previously shown to be associated with heart failure, cancer, and noncancer mortality.
Authors: Elsa S Strotmeyer; Alice M Arnold; Robert M Boudreau; Diane G Ives; Mary Cushman; John A Robbins; Tamara B Harris; Anne B Newman Journal: J Am Geriatr Soc Date: 2010-04 Impact factor: 5.562
Authors: Robert C Kaplan; Aileen P McGinn; Michael N Pollak; Lewis H Kuller; Howard D Strickler; Tom E Rohan; Anne R Cappola; XiaoNan Xue; Bruce M Psaty Journal: J Clin Endocrinol Metab Date: 2007-01-30 Impact factor: 5.958
Authors: Anne B Newman; Alice M Arnold; Michael C Sachs; Diane G Ives; Mary Cushman; Elsa S Strotmeyer; Jingzhong Ding; Stephen B Kritchevsky; Paulo H M Chaves; Linda P Fried; John Robbins Journal: J Am Geriatr Soc Date: 2009-01-29 Impact factor: 5.562
Authors: Robert C Kaplan; Aileen P McGinn; Michael N Pollak; Lewis Kuller; Howard D Strickler; Thomas E Rohan; Anne R Cappola; XiaoNan Xue; Bruce M Psaty Journal: Am Heart J Date: 2008-03-05 Impact factor: 4.749
Authors: Swapnil N Rajpathak; Aileen P McGinn; Howard D Strickler; Thomas E Rohan; Michael Pollak; Anne R Cappola; Lewis Kuller; XiaoNan Xue; Anne B Newman; Elsa S Strotmeyer; Bruce M Psaty; Robert C Kaplan Journal: Growth Horm IGF Res Date: 2007-09-27 Impact factor: 2.372
Authors: Robert C Kaplan; Aileen P McGinn; Michael N Pollak; Lewis Kuller; Howard D Strickler; Thomas E Rohan; XiaoNan Xue; Stephen B Kritchevsky; Anne B Newman; Bruce M Psaty Journal: J Am Geriatr Soc Date: 2008-02-27 Impact factor: 5.562
Authors: Michael P Brugts; Cornelia M van Duijn; Leo J Hofland; Jacqueline C Witteman; Steven W J Lamberts; Joseph A M J L Janssen Journal: Diabetes Date: 2010-02 Impact factor: 9.461
Authors: Evie van der Spoel; Maarten P Rozing; Jeanine J Houwing-Duistermaat; P Eline Slagboom; Marian Beekman; Anton J M de Craen; Rudi G J Westendorp; Diana van Heemst Journal: Aging (Albany NY) Date: 2015-11 Impact factor: 5.682
Authors: Ulrick Espelund; Andrew G Renehan; Søren Cold; Claus Oxvig; Lee Lancashire; Zhenqiang Su; Allan Flyvbjerg; Jan Frystyk Journal: Cancer Med Date: 2018-05-03 Impact factor: 4.452
Authors: Francesca D'Addio; Anna Maestroni; Emma Assi; Moufida Ben Nasr; Giovanni Amabile; Vera Usuelli; Cristian Loretelli; Federico Bertuzzi; Barbara Antonioli; Francesco Cardarelli; Basset El Essawy; Anna Solini; Ivan C Gerling; Cristina Bianchi; Gabriella Becchi; Serena Mazzucchelli; Domenico Corradi; Gian Paolo Fadini; Diego Foschi; James F Markmann; Emanuela Orsi; Jan Škrha; Maria Gabriella Camboni; Reza Abdi; A M James Shapiro; Franco Folli; Johnny Ludvigsson; Stefano Del Prato; Gianvincenzo Zuccotti; Paolo Fiorina Journal: Nat Commun Date: 2022-02-03 Impact factor: 17.694